Home/Pipeline/HDM5001

HDM5001

Advanced Solid Tumors

Phase IActive, Recruiting

Key Facts

Indication

Advanced Solid Tumors

Phase

Phase I

Status

Active, Recruiting

Company

Huadong Medicine (HD Medicine)

About Huadong Medicine (HD Medicine)

Huadong Medicine's mission is to become a global leader in pharmaceutical innovation, improving human health through the discovery and delivery of high-quality medicines. The company has achieved significant scale as one of China's largest and most valuable publicly traded pharma firms, with a robust commercial portfolio and a maturing R&D pipeline. Its strategy hinges on a dual approach: deepening its presence in the massive domestic market through commercialization and partnerships, while advancing a proprietary pipeline of novel biologics and small molecules to compete globally. Sustained high R&D investment and strategic business development are central to this growth plan.

View full company profile

Therapeutic Areas

Oncology Autoimmune Diseases Metabolic Diseases

Other Advanced Solid Tumors Drugs

Drug	Company	Phase	Status
NT219	Purple Biotech	Phase 1/2	Active
INDP-101	Indaptus Therapeutics	Phase 1	Active, not recruiting
PM14	PharmaMar	Phase 1/2	Active
Ecubectedin (PM54)	PharmaMar	Phase 1	Active
AP-202	Advance Pharmaceutical	Phase 1/2	Active, dose expansion
BI-1808	BioInvent International	Phase 1/2a	Active
GIGA-564	GigaGen	Phase 1	Active
Venadaparib (IDX-1197)	Idience	Phase 1a	Completed
VET3-TGI	KaliVir Immunotherapeutics	Phase 1	Active
IT-141 (Etoposide IVECT™)	Intezyne	Phase 1	Active
NC318	NextCure	Phase 1/2	Discontinued (Monotherapy)
VisAcT (18F-AraG) Imaging in Solid Tumors	CellSight Technologies	Phase 1/2	Active